Mochida Pharmaceutical Co., Ltd. (JP:4534)
:4534
4534 Stock Chart & Stats
¥3615.00
-¥40.00(-1.17%)
At close: 4:00 PM EST
¥3615.00
-¥40.00(-1.17%)
Day’s Range― - ―
52-Week Range¥2,836.00 - ¥3,965.00
Previous CloseN/A
Volume18.00K
Average Volume (3M)34.37K
Market Cap
¥122.84B
Enterprise Value¥98.72B
Total Cash (Recent Filing)¥54.69B
Total Debt (Recent Filing)¥830.00M
Price to Earnings (P/E)12.6
Beta0.65
Next Earnings
May 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.34%
Share Statistics
EPS (TTM)70.12
Shares Outstanding36,390,000
10 Day Avg. Volume38,620
30 Day Avg. Volume34,366
Financial Highlights & Ratios
PEG Ratio0.75
Price to Book (P/B)0.86
Price to Sales (P/S)1.07
P/FCF Ratio15.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)208.3
Revenue Forecast (FY)¥110.00B
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Equity BaseVery low debt and a robust equity ratio provide durable financial flexibility. This reduces refinancing risk, supports steady funding for R&D, licensing and commercial activities, and allows the company to absorb reimbursement or market shocks without jeopardizing operations.
Healthy Gross And Net MarginsSustained gross and net margins show structural operational efficiency and pricing power in core therapeutic areas. Margins protect earnings through revenue cyclicality, enabling reinvestment in product development, salesforce support and selective licensing without immediate margin erosion.
Strong Cash Generation Vs. EarningsA strong FCF-to-net-income ratio and improving operating cash flow indicate reliable internal funding for operations, R&D and licensing. This lessens dependence on external capital, supports sustained commercial programs and provides capacity for strategic investments over the medium term.
Bears Say
Declining Revenue TrendPersistent revenue contraction undermines long-term growth prospects and raises questions about product lifecycle management and market share. Continued declines force reliance on cost control or asset deals to sustain earnings, constraining investment in new product development and commercialization.
Volatile Free Cash Flow GrowthIrregular free cash flow complicates multi-year planning for R&D, licensing payments and capital expenditures. Volatility can necessitate opportunistic financing or cutbacks during downtimes, reducing predictability of shareholder returns and the firm's ability to consistently fund strategic initiatives.
Domestic Concentration & In‑licensing RelianceHeavy dependence on Japan prescription sales, MR-led promotion and in‑licensed products concentrates commercial risk. This limits geographic diversification, ties growth to domestic reimbursement and partner pipelines, and makes scaling vulnerable to regulatory or reimbursement shifts in Japan.
Mochida Pharmaceutical Co., Ltd. News
4534 FAQ
What was Mochida Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Mochida Pharmaceutical Co., Ltd. lowest stock price was ¥2836.00 and its highest was ¥3965.00 in the past 12 months.
What is Mochida Pharmaceutical Co., Ltd.’s market cap?
Mochida Pharmaceutical Co., Ltd.’s market cap is ¥122.84B.
When is Mochida Pharmaceutical Co., Ltd.’s upcoming earnings report date?
Mochida Pharmaceutical Co., Ltd.’s upcoming earnings report date is May 15, 2026 which is in 43 days.
How were Mochida Pharmaceutical Co., Ltd.’s earnings last quarter?
Mochida Pharmaceutical Co., Ltd. released its earnings results on Feb 06, 2026. The company reported ¥70.12 earnings per share for the quarter, beating the consensus estimate of N/A by ¥70.12.
Is Mochida Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Mochida Pharmaceutical Co., Ltd.’s price is currently Overvalued.
Does Mochida Pharmaceutical Co., Ltd. pay dividends?
Mochida Pharmaceutical Co., Ltd. pays a Semiannually dividend of ¥40 which represents an annual dividend yield of 2.34%. See more information on Mochida Pharmaceutical Co., Ltd. dividends here
What is Mochida Pharmaceutical Co., Ltd.’s EPS estimate?
Mochida Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mochida Pharmaceutical Co., Ltd. have?
Mochida Pharmaceutical Co., Ltd. has 36,390,000 shares outstanding.
What happened to Mochida Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Mochida Pharmaceutical Co., Ltd. reported an EPS of ¥70.12 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.537%.
Which hedge fund is a major shareholder of Mochida Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4534
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mochida Pharmaceutical Co., Ltd.
Mochida Pharmaceutical Co., Ltd. produces and sells pharmaceuticals, skincare products, and diagnostics solutions in Japan. The company provides cardiovascular, analgesic, gastrointestinal, neurological, anti-infective, antidiabetics, and anticancer products, as well as hormone and biological preparations, and biosimilars; diagnostic reagents, such as reagents for fertility/infertility and other reagents; and face and body care, hair care, and skincare products, as well as dermatology, psychiatry, obstetrics, and gynecology products. It also developing drugs for the treatment of intractable diseases. The company has collaboration agreements with Amarin Corporation plc for the development and commercialization of ethyl icosapentate products; and Gene Techno Science Co., Ltd. to develop new regenerative medicine for the treatment of digestive rare and intractable diseases, such as congenital isolated hypoganglionosis. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.
Technical Analysis
Kaken Pharmaceutical Co
―
Kissei Pharmaceutical Co
―
Towa Pharmaceutical Co
―
KYORIN Pharmaceutical Co.,Ltd.
―
SAWAI GROUP HOLDINGS Co., Ltd.
―
Options Prices
Currently, No data available
---